DOCSLIB.ORG

Achieving Pharmacare for All

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Achieving Pharmacare for All A PRESCRIPTION FOR CANADA: ACHIEVING PHARMACARE FOR ALL Final Report of the Advisory Council on the Implementation of National Pharmacare June 2019 A PRESCRIPTION FOR CANADA: ACHIEVING PHARMACARE FOR ALL Final Report of the Advisory Council on the Implementation of National Pharmacare June 2019 Health Canada is the federal department responsible for helping the people of Canada maintain and improve their health. Health Canada is committed to improving the lives of all of Canada’s people and to making this country’s population among the healthiest in the world as measured by longevity, lifestyle and effective use of the public health care system. Également disponible en français sous le titre : Une ordonnance pour le Canada : l’assurance-médicaments pour tous — Rapport final du Conseil consultatif sur la mise en œuvre d’un régime national d’assurance-médicaments To obtain additional information, please contact: Health Canada Address Locator 0900C2 Ottawa, ON K1A 0K9 Tel.: 613-957-2991 Toll free: 1-866-225-0709 Fax: 613-941-5366 TTY: 1-800-465-7735 E-mail: [email protected] © Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2019 Publication date: June 2019 This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged. Print Cat: H22-4/18-2019E PDF Cat: H22-4/18-2019E-PDF Pub: 190051 ISBN: 978-0-660-30975-0 ISBN: 978-0-660-30974-3 Table of Contents MESSAGE FROM THE CHAIR . 1 ACKNOWLEDGEMENTS . 5 EXECUTIVE SUMMARY . 7 LIST OF RECOMMENDATIONS . 17 1 INTRODUCTION . 25 1.1 The council’s mandate . 25 1.2 National dialogue . 26 1.3 Policy research and analysis. 28 1.4 What’s in the report . 28 2 DRUG COVERAGE IN CANADA TODAY . 29 2.1 The idea of pharmacare . 29 2.2 The evolution of medicare . 32 2.3 Public drug plans . 33 2.4 Private drug plans . 35 2.5 The changing drug landscape . 38 3 KEY CHALLENGES FACING CANADA’S PRESCRIPTION DRUG SYSTEM . 41 3.1 Fairness . 41 3.2 Cost . 44 3.3 Sustainability .. 48 3.4 Value for money . 51 3.5 The case for national pharmacare . 53 4 A PHARMACARE PLAN FOR CANADA . 55 4.1 Principles of national pharmacare . 55 4.2 Terms of coverage . 57 4.2.1 Who will national pharmacare cover? . 59 4.2.2 What drugs will pharmacare pay for? . .60 4.2.3 What costs will patients pay? . .60 4.3 The way forward . 63 iii A Prescription for Canada: Achieving Pharmacare for All 5 GETTING TO NATIONAL PHARMACARE . 65 5.1 Government collaboration . 65 5.2 Indigenous engagement . .66 5.3 Creating a Canadian drug agency . .68 5.4 Developing a national formulary . 73 5.5 Implementing a national formulary—starting with essential medicines . 76 5.6 National strategy on appropriate prescribing and use of drugs . 79 5.7 National strategy for expensive drugs for rare diseases . 80 6 FINANCING NATIONAL PHARMACARE . .85 6.1 Assessing the cost of national pharmacare . 85 6.1.1 The council’s drug spending model . .86 6.1.2 How drug spending will evolve with national pharmacare . .88 6.1.3 Savings in system wide spending under national pharmacare . 92 6.1.4 How the council’s projection of pharmacare costs compares with other estimates . 92 6.2 Financing national pharmacare . 93 6.2.1 Federal-provincial-territorial fiscal arrangements . 93 6.2.2 Revenue generation . 95 7 ENSURING THE SUCCESS OF NATIONAL PHARMACARE . 97 7.1 Legislation . 97 7.2 Transition support . .99 7.2.1 Provinces and territories . .99 7.2.2 Private insurance . 99 7.2.3 Pharmacists and the pharmaceutical industry . .100 7.2.4 Patient and public partnerships . 100 7.3 Information technology and drug data . 101 7.3.1 Upgrading drug plan IT systems . 101 7.3.2 Investing in drug data . 102 7.4 Supporting federal measures . 103 7.4.1 Streamlining drug reviews . 103 7.4.2 Regulating patented drug prices . 104 7.4.3 Supporting innovation and research . 105 iv Table of Contents 8 WHAT NATIONAL PHARMACARE WILL MEAN FOR CANADA . 107 8.1 For patients and their families . 107 8.2 For employees and businesses . 109 8.3 For the health care system and health care providers . 110 8.4 For citizens and taxpayers . 111 9 CONCLUSION . 113 ENDNOTES . 115 ANNEX 1: Biographies . 119 ANNEX 2: Order in Council . 123 ANNEX 3: National dialogue participants . 125 ANNEX 4: Overview of provincial and territorial drug plans . 134 ANNEX 5: Key characteristics of the pharmacare systems in comparator countries . 136 ANNEX 6: Drug spending model . 138 ANNEX 7: Other pharmacare models considered .. 164 ANNEX 8: Sex- and gender-based analysis . 168 v A Prescription for Canada: Achieving Pharmacare for All vi MESSAGE FROM THE CHAIR Canadians have considered the idea of universal drug coverage, as a complement to universal health care, for over five decades. For such a long-standing debate there is a surprising level of consensus. After hearing from many thousands of Canadians, we found a strongly held, shared belief that everyone in Canada should have access to prescription drugs based on their need and not their ability to pay, and delivered in a manner that is fair and sustainable. That’s why our council has recommended that Canada implement universal, single-payer public pharmacare. If the promise of universal health care is that Canadians are there for each other when we’re sick, by not including prescription drugs we’re placing a limit on that commitment. We may enter the hospital or the doctor’s office with equal access to health care, but we don’t go home with the same prospects for a healthier future, because prescription drug coverage varies greatly from person to person, and from province to province. There are too many people in our country who die prematurely or suffer needlessly in ill health because cost is a barrier to accessing prescription drugs. This gap—between our values and our reality—is growing because the nature of medicine is changing. When universal health care was first proposed, prescription drugs were important but not as commonly used and much less expensive. Today, drugs are the second-largest cost in Canadian health care, after hospitals and ahead of physician services. We heard from both public and private prescription drug providers that the current system is near the breaking point and in need of significant, even transformational, reform. The common refrain we heard from Canadians: we have to do better. Even though many Canadians have some form of coverage, Canada relies on a confusing patchwork of over 100 public prescription drug plans and over 100,000 private plans—with a variety of premiums, copayments, deductibles and annual limits. For a family or a single patient with a complex condition, those costs can add up to a significant barrier. 1 A Prescription for Canada: Achieving Pharmacare for All Approximately 20 per cent of Canadians have inadequate drug coverage or no coverage at all and must pay out of pocket. A recent study found almost 1 million Canadians had cut their household spending on food and heat to pay for medication. Another found that one in five households reported a family member who, in the past year, had not taken a prescribed medicine due to its cost. This uneven, inconsistent and tenuous patchwork in no way resembles a “system.” There is no single, uniform method in Canada for a child with asthma to get her inhaler. It depends on her family’s coverage. There is no one consistent way that all cancer patients obtain take-home cancer drugs or medicines for coping with chemotherapy side effects. Some pay more. Some pay less. Some don’t have access to those medicines at all. Over the past year, we saw provinces and territories taking action, working hard to provide better prescription drug coverage, but we also concluded that the federal government can and should do more, working in partnership with provincial and territorial governments, to ensure all Canadians can access the medicines they need. There is a cost to universal pharmacare and we understand that governments have fiscal limits. But universal, single-payer, public pharmacare can save billions by lowering the price we pay for prescription medicines and by avoiding the greater costs that accumulate when a manageable condition becomes a serious health crisis or when complications develop because someone could not afford to take medicine as prescribed. It might be the person recently laid off who stops taking medicines for preventing heart attack or stroke. They don’t feel an immediate, daily difference when they take those pills. So, they question the expense when money is tight. They mean to get back on the medicine when they get back on their feet. But time runs out. They end up in an emergency room in crisis. They may now need ongoing home care. Any return to work is delayed or maybe never happens. Barriers to accessing prescribed medication can and do result in additional visits to the doctor’s office, emergency departments and hospital inpatient wards, all costing our society much more than the cost of that preventive medicine. Improving access to prescription medicine improves health outcomes, reduces health care visits and saves billions in downstream health care costs. Our current fractured system also weakens Canada’s negotiating position with pharmaceutical companies. We pay some of the highest drug prices in the world. Other countries with universal pharmacare get better deals for the same drugs. Without price reductions, our public and private drug plans will continue to be strained.
Load more

Recommended publications
  • Health Claim About Vegetables and Fruit and Heart Disease
    Summary of Health Canada's Assessment of a Health Claim about Vegetables and Fruit and Heart Disease Summary of Health Canada's Assessment of a Health Claim about Vegetables and Fruit and Heart Disease December 2016 Bureau of Nutritional Sciences, Food Directorate, Health Products and Food Branch 1 Summary of Health Canada's Assessment of a Health Claim about Vegetables and Fruit and Heart Disease Health Canada is the federal department responsible for helping the people of Canada maintain and improve their health. We assess the safety of drugs and many consumer products, help improve the safety of food, and provide information to Canadians to help them make healthy decisions. We provide health services to First Nations people and to Inuit communities. We work with the provinces to ensure our health care system serves the needs of Canadians. Également disponible en français sous le titre : Résumé de l’évaluation par Santé Canada d’une allégation santé au sujet des légumes et des fruits et de la maladie du cœur To obtain additional information, please contact: Health Canada Address Locator 0900C2 Ottawa, ON K1A 0K9 Tel.: 613-957-2991 Toll free: 1-866-225-0709 Fax: 613-941-5366 TTY: 1-800-465-7735 E-mail: [email protected] This publication can be made available in alternative formats upon request. © Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2016 Publication date: December 2016 This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged.
    [Show full text]
  • From Signal Detection to Safety Assessment and Selection
    3/13/2017 HEALTH CANADA’S PHARMACOVIGILANCE ACTIVITIES FOR MARKETED PHARMACEUTICAL PRODUCTS: FROM SIGNAL DETECTION TO SAFETY ASSESSMENTS AND SELECTION OF RISK MITIGATION STRATEGY Nadiya Jirova M.Sc. Marketed Pharmaceuticals and Medical Devices Bureau Marketed Health Products Directorate Health Canada CAPRA meeting, January 2017 Outline Overview of Pharmacovigilance at MHPD Signal Detection • Signal Detection Working Groups • Prioritization of safety issues Signal assessment • Work process • Sources of data • Considerations • Options • Recommendations • Examples of Signal Assessments Summary Safety Reviews http://www.hc-sc.gc.ca/ewh-semt/pubs/occup-travail/balancing_six-equilibre_six/index-eng.phpQuestions 2 1 3/13/2017 MPMDB within Health Canada Health Canada Health Products Branches and Food Branch Directorates Marketed Health Products Directorate Marketed Pharmaceuticals Bureaux and Medical Devices Bureau 3 Lifecycle Approach to Product Vigilance MPMDB activities span the lifecycle of a Health Product in Canada 4 2 3/13/2017 MPMDB Activities within MHPD Medication PSUR Policy InfoWatch Complementary Advertising Incidents Review Development Activities Signal Signal Risk RMP Review Detection Assessment Minimization review Activities AE Risk Comms Risk Comms Risk Comms Risk Comms Basic Reg. collection Pharmac. Biologics NHPs Med. Dev. Activities 5 Pharmacovigilance at MHPD Signal detection working groups • Safety literature • Canada Vigilance database • Foreign agency actions • Info submitted by MAH • TPD Bureau requests Other Emerging
    [Show full text]
  • Health Canada's Biomonitoring Approach
    Health Canada’s Biomonitoring Approach Environmental Health Surveillance Workshop February 2013 Douglas Haines Chemicals Surveillance Bureau Environmental and Radiation Health Sciences Directorate Health Canada Presentation Objectives • To provide an overview of Health Canada’s biomonitoring approach • Main focus on the biomonitoring component of the Canadian Health Measures Survey • Framework and infrastructure for biomonitoring 2 Chemicals Management Plan In 2006, the Government of Canada launched the Chemicals Management Plan (CMP) to advance and improve the management of chemical substances and safeguard the health of Canadians. Risk Assessment Research Reporting, Risk Communication Management & Cooperation Monitoring & Surveillance Compliance, Promotion & Enforcement 3 Human Biomonitoring Context Knowledge Action Dissemination Exposure Biomonitoring Users synthesis & •Regulatory decision making •Public health Supporting Science: Identifying Priorities • Study design • Chemicals • Laboratory methods/validation • Population • Biomarker development • Geographic area • Pilot studies • Statistical methods • Tools to interpret biomonitoring data 4 Health Canada’s Multi-Pronged Canadian Health Measures Survey Biomonitoring Approach • General population (n=5,000-6,000) • Nationally representative Cycle 1 – 15 sites (2007-2009) Cycle 2 – 18 sites (2009-2011) Cycle 3 – 16 sites (2012-2013) Maternal-Infant Research on Environmental Chemicals • Pregnant women-infant cohort (n=2,000) • 10 study centres • Targeted recruitment First Nations Biomonitoring
    [Show full text]
  • Corporate Planning Highlights 2018-2021
    CORPORATE PLANNING HIGHLIGHTS 2018-2021 The Agency will improve the services it provides to Canadians so that clients receive the assistance that they deserve and rightly expect. —The Honourable Diane Lebouthillier, P.C., M.P Minister of National Revenue A MESSAGE FROM THE MINISTER This plan shows how the CRA, through innovation and the services it offers to Canadians, is striving to be a world-class tax and benefit administration. We face many challenges, and I am proud of the tremendous work that the Agency’s 40,000 employees are doing. I am especially proud of their ongoing efforts to improve and Meanwhile, Canadians can be assured that the Agency expand the services the CRA offers, and to implement more effective, fair and is taking action against those who seek to evade, efficient compliance measures to protect Canada’s revenue base. or aggressively avoid, their tax obligations. Further to recent revelations in both the Panama Papers and Paradise Papers, we undertook major work and In my role as Minister, I especially want to see the concrete and meaningful steps to make CRA services invested significant funds to crack down on tax evasion CRA exemplify service excellence in all aspects of its to northern residents more helpful and easier to use; and aggressive tax avoidance. Our goal is to ensure a operations. The Fall 2017 Report of the Auditor General supporting the Government’s goal of renewing and fair tax system and a level playing field for all Canadians. on the operations of our call centres shows that we establishing a better relationship with Indigenous peoples; Non compliance with Canada’s tax laws will not be do not always provide Canadians with the help they and expanding the popular and very useful Community tolerated as it erodes the integrity of the tax system.
    [Show full text]
  • A New Review Mechanism for the RCMP’S National Security Activities
    ARCHIVED - Archiving Content ARCHIVÉE - Contenu archivé Archived Content Contenu archivé Information identified as archived is provided for L’information dont il est indiqué qu’elle est archivée reference, research or recordkeeping purposes. It est fournie à des fins de référence, de recherche is not subject to the Government of Canada Web ou de tenue de documents. Elle n’est pas Standards and has not been altered or updated assujettie aux normes Web du gouvernement du since it was archived. Please contact us to request Canada et elle n’a pas été modifiée ou mise à jour a format other than those available. depuis son archivage. Pour obtenir cette information dans un autre format, veuillez communiquer avec nous. This document is archival in nature and is intended Le présent document a une valeur archivistique et for those who wish to consult archival documents fait partie des documents d’archives rendus made available from the collection of Public Safety disponibles par Sécurité publique Canada à ceux Canada. qui souhaitent consulter ces documents issus de sa collection. Some of these documents are available in only one official language. Translation, to be provided Certains de ces documents ne sont disponibles by Public Safety Canada, is available upon que dans une langue officielle. Sécurité publique request. Canada fournira une traduction sur demande. A New Review Mechanism for the RCMP’s National Security Activities Commission of Inquiry into the Actions of Canadian Officials in Relation to Maher Arar © Her Majesty the Queen in Right of Canada, represented by the Minister of Public Works and Government Services, 2006 Cat.
    [Show full text]
  • Canada Revenue Agency Annual Report to Parliament 2007-2008
    Canada Revenue Agency Annual Report to Parliament 2007-2008 RC4425 E REV08 About the CRA Who we are The Canada Revenue Agency (CRA) administers the Income Tax Act and other taxes and is the principal revenue collector in the country. We also distribute benefit payments to millions of Canadians. We strive to ensure that Canadians: • pay their required share of taxes; • receive their rightful share of entitlements; and • are provided with an impartial and responsive review of contested decisions. Our foundation of trust Building our foundation of trust is critical to achieving our mandate. Canadians respect our integrity and professionalism. Our respect and co-operation are the basis for our dealings with all Canadians and will guide us forward. Trust begins with CRA’s values that reflect our principles and beliefs and guide our behaviour and practices. These values are integrity, professionalism, respect, and co-operation. Our role in Canada’s tax and benefit systems A well-functioning tax and benefit system is essential to a healthy economy, a sustainable infrastructure, and a strong democracy. Some of the tax revenue we collect is redistributed to taxpayers by us in the form of benefit payments or tax credits. Other tax revenue is provided to our federal, provincial, territorial, and First Nations government clients to finance their programs and services for Canadians. 2007-2008 CRA in Perspective Our Mission To administer tax, benefits, and related programs, and to ensure compliance on behalf of governments across Canada, thereby contributing to the ongoing economic and social well-being of Canadians. Our Promise Contributing to the well-being of Canadians and the efficiency of government by delivering world-class tax and benefit administration that is responsive, effective, and trusted.
    [Show full text]
  • CANADIAN PARKS and PROTECTED AREAS: Helping Canada Weather Climate Change
    CANADIAN PARKS AND PROTECTED AREAS: Helping Canada weather climate change Report of the Canadian Parks Council Climate Change Working Group Report prepared by The Canadian Parks Council Climate Change Working Group for the Canadian Parks Council Citation: Canadian Parks Council Climate Change Working Group. 2013. Canadian Parks and Protected Areas: Helping Canada Weather Climate Change. Parks Canada Agency on behalf of the Canadian Parks Council. 52 pp. CPC Climate Change Working Group members Karen Keenleyside (Chair), Parks Canada Linda Burr (Consultant), Working Group Coordinator Tory Stevens and Eva Riccius, BC Parks Cameron Eckert, Yukon Parks Jessica Elliott, Manitoba Conservation and Water Stewardship Melanie Percy and Peter Weclaw, Alberta Tourism, Parks and Recreation Rob Wright, Saskatchewan Tourism and Parks Karen Hartley, Ontario Parks Alain Hébert and Patrick Graillon, Société des établissements de plein air du Québec Rob Cameron, Nova Scotia Environment, Protected Areas Doug Oliver, Nova Scotia Natural Resources Jeri Graham and Tina Leonard, Newfoundland and Labrador Parks and Natural Areas Christopher Lemieux, Canadian Council on Ecological Areas Mary Rothfels, Fisheries and Oceans Canada Olaf Jensen and Jean-François Gobeil, Environment Canada Acknowledgements The CPC Climate Change Working Group would like to thank the following people for their help and advice in preparing this report: John Good (CPC Executive Director); Sheldon Kowalchuk, Albert Van Dijk, Hélène Robichaud, Diane Wilson, Virginia Sheehan, Erika Laanela, Doug Yurick, Francine Mercier, Marlow Pellat, Catherine Dumouchel, Donald McLennan, John Wilmshurst, Cynthia Ball, Marie-Josée Laberge, Julie Lefebvre, Jeff Pender, Stephen Woodley, Mikailou Sy (Parks Canada); Paul Gray (Ontario Ministry of Natural Resources); Art Lynds (Nova Scotia Department of Natural Resources).
    [Show full text]
  • Guidance Document Information and Submission Requirements for Biosimilar Biologic Drugs
    Guidance Document Information and Submission Requirements for Biosimilar Biologic Drugs Published by authority of the Minister of Health Date Adopted 2010-03-05 Revised Date 2016-11-14 Administrative Changes Date 2017-04-20 Health Products and Food Branch Information and Submission Requirements for Health Canada Biosimilar Biologic Drugs Guidance document Our mission is to help the people of Canada Our mandate is to take an integrated approach to managing maintain and improve their health. the health-related risks and benefits of health products and Health Canada food by: minimizing health risk factors to Canadians while maximizing the safety provided by the regulatory system for health products and food; and, promoting conditions that enable Canadians to make healthy choices and providing information so that they can make informed decisions about their health. Health Products and Food Branch © Her Majesty the Queen in Right of Canada as represented by the Minister of Health, 2017 Available in Canada through Health Canada – Publications Address Locator 0900C2 Ottawa, Ontario K1A 0K9 E-mail: [email protected] Telephone: 613-957-2991, 1-866-225-0709 Web address: www.hc-sc.gc.ca/index-eng.php Également disponible en français sous le titre : Ligne directrice - Exigences en matière de renseignements et de présentation relatives aux médicaments biologiques biosimilaire ii Revised Date: 2016-11-14 Health Canada Information and Submission Requirements for Guidance document Biosimilar Biologic Drugs Foreword Guidance documents are meant to provide assistance to industry and health care professionals on how to comply with governing statutes and regulations. Guidance documents also provide assistance to staff on how Health Canada mandates and objectives should be implemented in a manner that is fair, consistent, and effective.
    [Show full text]
  • D'amico Family Wealth Management Group of RBC Dominion Securities Presents Étienne Gadbois and Stephen Solomon from De Grandpré Chait, Lawyers
    D'Amico Family Wealth Management Group Of RBC Dominion Securities Presents Étienne Gadbois and Stephen Solomon from De Grandpré Chait, Lawyers "CRA and RQ in 2015 : You can run but you can’t hide! The positions taken by CRA and RQ have been subject to a great deal of media attention. This presentation will provide an overview of the major GST/QST audit issues as well as an update of the voluntary disclosures programs" Angelo D’Amico Christiana Kavadas Dario Falso Celina Toia FCSI, CIM, CPA, CMA, CGA, CSWP B. Comm. Associate Marketing Consultant Vice President - Portfolio Manager Associate Tel: (514) 878-5049 Tel: (514) 878-5196 Tel: (514) 878-5056 Email: [email protected] Email: [email protected] Email: [email protected] Web : http://www.damicofamilywealthmanagementgroup.ca March 11, 2015 Business Insurance Construction Taxation Real estate Insolvency Litigation Intellectual property Debt recovery CRA AND RQ IN 2015: YOU CAN RUN BUT YOU CAN’T HIDE! Presented by: Étienne Gadbois, lawyer Stephen Solomon, lawyer Your best partner D’Amico Family Wealth Management Group | RBC Dominion Securities Inc. March 11, 2015 Table of Contents 1. Contextualization 2. Voluntary Disclosures 3. GST/QST Issues in 2015: 3.1. Real Estate: Joint Venture Election and Bare Trust Issues 3.2 Construction and Employment Agencies: False Invoicing (or is it?) 3.3 Wholesalers: Sale of Tobacco Products (and other products) to Natives 3.4 Corporate Transactions and Elections 3.5 Application of Serious Offences Provision 4. Where do we stand today? Business Insurance Construction Taxation Real estate Insolvency Litigation Intellectual property Debt recovery 1.
    [Show full text]
  • Helpful Resources
    INTERVENTION Module 16: Helpful resources In this module: 24-hour emergency/crisis lines: Province-wide; Provincial resources; Regional Health Authorities; Women’s Policy Office - Violence Prevention Initiative and Regional Coordinating Committees against Violence; Helpful resources: Preventing violence against older persons; National resources; Federal government; My important contacts; and, Links: Internet resources. There are many resources in this province that may be helpful to you if you are: A service provider to older victims of violence; An older person who is a victim of violence; An older person at risk of violence; A perpetrator of violence; Someone with the potential to become violent; and, Concerned about someone in any of the above situations. In this module you will find resources that are available nationally, provincially and within your region or community. Since violence against older persons can take many forms, it is necessary to be able to call upon a range of resources. Availability of resources may depend on the community or region. Some programs may not be available or accessible in rural or remote regions of the province. There may be waiting lists for services. Suitable emergency housing may not be available. In these situations, advocacy becomes very important. PREVENTING VIOLENCE AGAINST OLDER PERSONS • education and training manual 193 It may help to learn about resources for victims of crime or family violence. Service providers and other helpers must know about these resources, and should be able to link older persons with needed services and programs. For more violence prevention information, please visit the Violence Prevention Initiative website, www.gov.nl.ca/vpi.
    [Show full text]
  • 2018 | Inventory of International and Intergovernmental Agreements, Continued
    2017 –2018 Inventory of International and Intergovernmental Agreements 2017– 2018 Inventory of International and Intergovernmental Agreements Effective Date Parties / Title Ministry / Agency 01-Sep-15 Alberta-British Columbia: Advanced Education, Skill Advanced Education and Training, “Interprovincial Agreement Amendment – Cardiovascular Perfusion” 20-Apr-17 Alberta-China: Guanghua International Education Association, Advanced Education “Memorandum of Understanding on Cooperation in the Field of Health and Care of the Elderly Relating to Education, Professional Development and Research” 18-May-17 Alberta-Saskatchewan: Advanced Education, “Interprovincial Advanced Education Agreement – Occupational Therapy” 10-Jul-17 Alberta-Canada: Statistics Canada, “Third Amending Agreement Advanced Education Concerning Access to Statistics Confidential Microdata on Benefits to Post-Secondary Education Project” 31-Jul-17 Alberta-British Columbia: Queen’s Printer, Citizen’s Services, Advanced Education “Individual Learning Modules Licence Agreement” 01-Aug-17 Alberta-Northwest Territories: Education, Culture and Advanced Education Employment, “Memorandum of Understanding for Apprenticeship Technical Training Seats” 01-Aug-17 Alberta-Nunavut: Family Services, “Memorandum of Advanced Education Understanding for Apprenticeship Technical Training Seats” 01-Aug-17 Alberta-Yukon: Education, “Memorandum of Understanding for Advanced Education Apprenticeship Technical Training Seats” 16-Aug-17 Alberta-Canada: Statistics Canada, “Agreement Concerning the Advanced
    [Show full text]
  • Chapter 1: All About Taxation
    Learning About Tax with Intuit Profile 2021 Chapter 1 All About Taxation Learning Objectives At this chapter’s end Additional Resources This document provides numerous students will understand: resources to accounting professionals. Refer to these sites to explore additional • The history of taxation training opportunities • How tax dollars are raised and disbursed Professional Accounting Software • The role of the Canda Revenue Agency Tax Preparation & efiling Return Software • A taxpayer’s filing options Professional Tax Software Training • Taxpayer responsibilities • How to get information to help you file a tax return • How to access and use CRA electronic services Copyright Copyright 2021 Intuit, Inc. Intuit, Inc. All rights reserved. 5100 Spectrum Way, Mississauga, ON L4W 5S2 Trademarks ©2021 Intuit Inc. All rights reserved. Intuit, the Intuit logo, Intuit ProFile, ProAdvisor, and QuickBooks, among others, are trademarks or registered trademarks of Intuit, Inc. in Canada and other countries. Other parties’ marks are the property of their respective owners. Notice to Readers The publications distributed by Intuit Inc. are intended to assist educators by providing current and accurate information. However, no assurance is given that the information is comprehensive in its coverage or that it is suitable in dealing with a particular situation. Accordingly, the information provided should not be relied upon as a substitute for independent research. Intuit Inc. does not render any accounting, legal, or other professional advice nor does it have any responsibility for updating or revising any information presented herein. Intuit Inc. cannot warrant that the material contained herein will continue to be accurate or that it is completely free of errors when published.
    [Show full text]